Thalidomide
- Generic Name
- Thalidomide
- Brand Names
- Thalomid, Thalidomide BMS (previously Thalidomide Celgene), Thalidomide Lipomed
- Drug Type
- Small Molecule
- Chemical Formula
- C13H10N2O4
- CAS Number
- 50-35-1
- Unique Ingredient Identifier
- 4Z8R6ORS6L
- Background
A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating the release of inflammatory mediators like tumor necrosis factor-alpha (TNF-a) and other cytokine action. Due to severe teratogenicity, pregnancy must be excluded before the start of treatment and patients must enrol in the THALIDOMID Risk Evaluation and Mitigation Strategy (REMS) program to ensure contraception adherence.
- Indication
Thalidomide is primarily used for the acute treatment and maintenance therapy to prevent and suppress the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL).
- Associated Conditions
- Aphthous Stomatitis, Chronic Graft-Versus-Host Disease, Erythema Nodosum Leprosum, Multiple Myeloma (MM), Primary Amyloidosis, Uremic Pruritus, Waldenström's Macroglobulinemia (WM), Moderate Erythema nodosum leprosum, Refractory Graft versus host disease, Severe Erythema nodosum leprosum, Treatment naive multiple myeloma
The Therapeutic Effect of Thalidomide in Syringomyelia
- First Posted Date
- 2024-02-20
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- Xuanwu Hospital, Beijing
- Target Recruit Count
- 30
- Registration Number
- NCT06268093
- Locations
- 🇨🇳
Fengzeng Jian, Beijing, Beijing City, China
Comparison Of Efficacy And Safety Of Thalidomide Vs Hydroxyurea In Thalassemia Patients: A Single-Centre Pilot Study.
- First Posted Date
- 2024-02-02
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- National Institute of Blood and Marrow Transplant (NIBMT), Pakistan
- Target Recruit Count
- 24
- Registration Number
- NCT06239389
- Locations
- 🇵🇰
National Institute of Blood Diseases and Bone Marrow Transplantation, Karachi, Sindh, Pakistan
Thalidomide Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP)
- Conditions
- Lung Cancer, Nonsmall CellEsophageal Carcinoma
- Interventions
- First Posted Date
- 2024-01-30
- Last Posted Date
- 2024-03-29
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 132
- Registration Number
- NCT06231680
- Locations
- 🇨🇳
Ying Liu, Zhengzhou, Henan, China
🇨🇳The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China
Deciphering Effects of Thalidomide on Red Blood Cells in Transfusion Dependents Beta Thalassemia Patients
- First Posted Date
- 2023-11-24
- Last Posted Date
- 2023-11-24
- Lead Sponsor
- Blood Care Clinic
- Target Recruit Count
- 200
- Registration Number
- NCT06146478
- Locations
- 🇵🇰
Blood Care Clinic, Peshawar, Khyber Pakhtunkhwa, Pakistan
Safety & Efficacy of Thalidomide in Children With Transfusion Dependent Thalassemia
- Conditions
- Transfusion-dependent Thalassemia
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-10-24
- Last Posted Date
- 2024-04-09
- Lead Sponsor
- Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
- Target Recruit Count
- 60
- Registration Number
- NCT06098014
- Locations
- 🇧🇩
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Thalidomide to Chemotherapy Related Nausea and Vomiting in Pancreatic Cancer
- Conditions
- Pancreatic Cancer Stage IVChemotherapy-induced Nausea and Vomiting
- Interventions
- First Posted Date
- 2023-08-30
- Last Posted Date
- 2023-11-24
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 100
- Registration Number
- NCT06017284
- Locations
- 🇨🇳
Shanghai Cancer Center, Shanghai, Shanghai, China
The Clinical Efficacy and the Changes of Immune Cells Subsets With Bioagents in Ankylosing Spondylitis Patients
- Conditions
- Ankylosing Spondylitis
- Interventions
- First Posted Date
- 2022-09-02
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Qilu Hospital of Shandong University
- Target Recruit Count
- 100
- Registration Number
- NCT05527444
- Locations
- 🇨🇳
Qilu Hospital, Jinan, Shandong, China
A Study of Thalidomide in the Treatment of Refractory Uremic Pruritus
- First Posted Date
- 2022-09-01
- Last Posted Date
- 2022-09-01
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT05525234
Trifluridine/Tipiracil (TAS-102) With or Without Thalidomide for the Treatment of Metastatic Colorectal Cancer
- First Posted Date
- 2022-03-04
- Last Posted Date
- 2022-03-18
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 120
- Registration Number
- NCT05266820
- Locations
- 🇨🇳
First Affiliated Hospital of Fujian Medical University, Fuzhou, China
🇨🇳Fuzhou First Hospital affiliated to Fujian Medical University, Fuzhou, China
🇨🇳The Third People's Hospital affiliated to Fujian University of Chinese Medicine, Fuzhou, China
Thalidomide Combined With Chemotherapy and Monotherapy for Maintenance Treatment for Her2-negative Advanced GC
- Conditions
- Gastric Cancer Metastatic to Liver
- Interventions
- First Posted Date
- 2022-01-20
- Last Posted Date
- 2022-01-20
- Lead Sponsor
- Qilu Hospital of Shandong University
- Target Recruit Count
- 106
- Registration Number
- NCT05198856
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.